AzTrials
AzTrials

Tracheostomized PatientsNCT07714967

Effects of a Perma-h Model Mobile-based Rehabilitation Support Program on Hope, Self-efficacy, Perceived Social Support and Rehabilitation Outcomes in Post- Tracheostomy Oral Cancer Patients

A study testing PERMA-H model mobile-based rehabilitation support program in people with Tracheostomized Patients and Decanulation, run by Hainan Medical College at 2 sites in 2 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study (exploratory sequential design; mixed-methods study) is to evaluate whether a PERMA-H model mobile-based rehabilitation support program delivered to post-tracheostomy oral cancer patients can improve psychological and rehabilitation outcomes, compared with a control group receiving usual… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
PERMA-H model mobile-based rehabilitation support program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
2 sitesin 2 countries
Study dates
1 Aug 2026to 1 Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged ≥18 years
  • Pathologically diagnosed with oral squamous cell carcinoma and undergoing, or scheduled to undergo, tracheostomy followed by decannulation
  • Fully conscious, with a Glasgow Coma Scale score of 15, and able to successfully complete the Three-Step Command Test, indicating intact comprehension ability
  • Able to communicate effectively through verbal speech or alternative methods, including writing, gestures, electronic device input, or voice-assisted tools
  • Able to use WeChat independently or after brief guidance, without communication barriers
  • Has at least one regular family caregiver; both the patient and caregiver fully understand the study content and voluntarily provide written informed consent
  • Free from severe cardiovascular, cerebrovascular, hepatic, renal, or pulmonary disease

Who cannot join

  • Presence of other serious malignancies or extensive tumor metastasis
  • Previous or current diagnosis of severe mental illness, such as schizophrenia or severe bipolar disorder
  • Significant cognitive impairment, severe depressive symptoms, or suicide risk that precludes effective participation in psychological interventions
  • Inability to complete assessments or interventions due to severe hearing, visual, or language impairments
  • Inability to communicate effectively through any available alternative means
  • Lack of access to a smartphone and absence of a designated caregiver
Show all 9Show fewer
  • Explicit unwillingness or inability to use a mobile-based rehabilitation support program
  • Unexpected inability to complete the full intervention cycle, including planned hospital transfer or prolonged loss to follow-up
  • Concurrent participation in other clinical studies primarily focused on psychological or mobile health interventions that could confound study outcomes

Trial locations and contacts

2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Mingxiang Li, Master contact

+8618389291371

1364044138@qq.com

2 sites in 2 countries

China1 site
  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan

    Mingxiang Li, Master, +8618389291371, 1364044138@qq.com

Other trials in China

Malaysia1 site
  • The Affiliated Hospital of University of Malaya

    Kuala Lumpur, Kuala Lumpur

    Pinglei Chui, Dr., +60127128893, chuipinglei@um.edu.my

Other trials in Malaysia

About this study

The goal of this study (exploratory sequential design; mixed-methods study) is to evaluate whether a PERMA-H model mobile-based rehabilitation support program delivered to post-tracheostomy oral cancer patients can improve psychological and rehabilitation outcomes, compared with a control group receiving usual care/standard support. The study will focus on post-tracheostomy oral squamous cell carcinoma (OSCC) patients (aged ≥18 years) who are undergoing or scheduled to undergo tracheostomy followed by decannulation, and who have adequate communication ability and caregiver support.

The main questions it aims to answer are:

Read more

Does the PERMA-H model mobile-based rehabilitation support program improve patients' hope? (primary hypothesis/outcome measure 1) Does the PERMA-H model mobile-based rehabilitation support program improve patients' self-efficacy, perceived social support, and rehabilitation outcomes? (primary hypothesis/outcome measure 2) If there is a comparison group, researchers will compare the PERMA-H model mobile-based rehabilitation support program (intervention group) to a control group receiving standard/usual care (control group) to determine differences in outcomes between groups.

Participants will be asked to complete the main study tasks, including:

participating in qualitative interviews to explore their digital needs, expectations, and experiences regarding psychosocial care (Phase I); using the WeChat mini-program platform that incorporates a PERMA-H evidence-based module set and a chatbot (Decannulationbot / Digital rehabilitation Assistant, DDA) as part of the rehabilitation support program; completing validated assessments at study endpoints to measure hope (Herth Hope Index), self-efficacy (General Self-Efficacy Scale), and perceived social support (Perceived Social Support Scale), as well as rehabilitation-related outcomes (including rehabilitation willingness/participation and functional measures such as swallowing function and speech intelligibility as rated by speech-language pathologists).

Expected outcomes include: comprehensive qualitative findings to inform the content and delivery of digital psychosocial support; a functional mobile intervention platform with evidence-based modules validated through expert appraisal and pilot testing; and statistically significant improvements in hope, self-efficacy, perceived social support, and rehabilitation outcomes in the intervention group compared with the control group.

Being tested
PERMA-H model mobile-based rehabilitation support program
Keywords
PERMA-H, chatbot, Digital Rehabilitation Support, MODEL MOBILE
Medical subject headings
Mouth Neoplasms, Squamous Cell Carcinoma of Head and Neck, Psychological Well-Being, Speech Intelligibility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PERMA-H model mobile-based rehabilitation support programBehavioural

    The DDA comprised seven functional modules-Awakening Mind (P), Flow Experience (E), Supportive Connection (R), Meaning Reconstruction (M), Achievement Motivation (A), Self-Management (H), and Helpline. Each module corresponded to a specific element in each intervention design.The intervention commenced during the week of decannulation. An initial one-on-one, face-to-face session was conducted in hospital to introduce the DDA platform and explain key precautions. The remaining six sessions were completed by participants independently at home using DDA. On each intervention day, reminder messages were sent via Decannulationbot and WeChat groups. Based on prior evidence, the intervention was delivered over four weeks, with two sessions per week (35 minutes per session), completing one module per session, and a three-day interval between sessions to allow practice and consolidation.

Study groups in NCT07714967
Study groupRoleWhat they receive
PERMA-H model mobile-based rehabilitation support programExperimentalNot described
Receives: Behavioral: PERMA-H model mobile-based rehabilitation support program
routine nursing careNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hope

    The Herth Hope Index is widely used in clinical research to assess hope levels among adult patients. The instrument shows good reliability, with a Cronbach's α of 0.85. Developed by Herth (1992) as a shortened version of the original 30-item Hope Scale, it was translated and culturally adapted for China by Zhao (1997), resulting in a three-dimensional structure: positive attitude toward reality and the future (4 items), taking positive actions (4 items), and maintaining close relationships with others (4 items). Each item is rated on a 4-point Likert scale, ranging from 1 ("strongly disagree") to 4 ("strongly agree"), with Items 3 and 6 reverse-scored. The total score ranges from 12 to 48, with higher scores reflecting greater levels of hope. Specifically, scores of 12-23 indicate low hope, 24-35 indicate moderate hope, and 36-48 indicate high hope.

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

Secondary outcomes (6)
  1. perceived social support

    The Perceived Social Support Scale measures individuals' subjective perception of social support. Widely used in psychology, medicine, and sociology, it demonstrates strong reliability and validity. Developed by Zimet et al. (1990) and revised by Jiang (2001) for cultural adaptation, the Chinese version replaced the "other support" dimension with "support from leaders, relatives, and colleagues," yielding a Cronbach's α of 0.92. The scale includes three dimensions-family support, friend support, and support from leaders, relatives, and colleagues-each comprising four items. Responses are rated on a 7-point Likert scale (1 = "strongly disagree" to 7 = "strongly agree"), yielding a total score of 12-84. Scores of 12-36, 37-60, and 61-84 indicate low, moderate, and high PSS, respectively.

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

  2. self-efficacy

    The General Self-Efficacy Scale, developed by Schwarzer and Jerusalem (1995), originally comprised 20 items and was later refined to 10. It has been translated into more than 20 languages for global use. The Chinese version, translated and validated by Wang et al. (2001), measures individuals' confidence in managing challenges. Reported Cronbach's α coefficients for this version range from 0.87 to 0.96, indicating strong reliability and validity. Each item is rated on a 4-point Likert scale ("not at all true," "somewhat true," "mostly true," "completely true"), with scores ranging from 1 to 4. The total score ranges from 10 to 40, with higher scores reflecting stronger perceived self-efficacy. Based on the total score, self-efficacy can be categorized into three levels: scores below 20 indicate low self-efficacy, scores between 20 and 30 indicate moderate self-efficacy, and scores above 30 indicate high self-efficacy.

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

  3. rehabilitation willingness

    The Rehabilitation Willingness Questionnaire, developed by Liu et al. (2011) based on the TPB, assesses stroke patients' willingness to engage in rehabilitation. The instrument shows good reliability, with Cronbach's α = 0.79. It comprises three dimensions: behavioral attitude (3 items), subjective norms (4 items), and perceived behavioral control (5 items). Each item is rated on a 5-point Likert scale, producing total scores of 12-60, where higher scores indicate stronger rehabilitation willingness. Scores are categorized as low (12-27), moderate (28-43), and high (44-60).

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

  4. Swallowing function assessment

    Swallowing function was assessed using the water swallowing test proposed by Toshio Kubota, which provides clear grading criteria and is simple to administer. During the assessment, patients are seated and instructed to drink 30 mL of warm water, while swallowing frequency and the presence of coughing are observed. Swallowing performance is graded as follows: 1 point-swallowing the water in a single attempt; 2 points-swallowing the water in two or more attempts without coughing; 3 points-swallowing the water in a single attempt with coughing; 4 points-swallowing the water in two or more attempts with coughing; and 5 points-unable to swallow all the water with frequent coughing. Scores of 1-2 indicate normal swallowing function, whereas scores of 3-5 indicate dysphagia.

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

  5. Speech intelligibility assessment

    Speech intelligibility was assessed using the Hofstetter Speech Intelligibility Test, which evaluates the extent to which a patient's speech can be understood by unfamiliar listeners.The assessment was conducted by trained clinicians during routine clinical evaluation, and the resulting scores were extracted from medical records for analysis. Speech intelligibility (%)

    = (Number of words/syllables correctly understood by listeners)/ (Total number of words/ syllables presented). For example, if listeners correctly understand 42 out of 50 words, the speech intelligibility score is 84%, a comprehension level of 90% - 100% indicates that the speech is basically completely understandable, 75% - 89% represents a slight decline, 50% - 74% indicates a moderate decline, 25% - 49% represents a severe decline, and anything below 25% suggests extremely severe impairment in speech comprehension.

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

  6. the number of rehabilitation sessions

    During the early phase of rehabilitation, increasing session frequency is associated with substantial gains in neuroplasticity and motor function recovery. However, once the cumulative number of sessions approaches approximately 30, therapeutic effects tend to plateau. Although additional sessions may yield modest improvements, marginal benefits diminish, and excessive rehabilitation can lead to fatigue, reduced adherence, and increased financial burden.Accordingly, this study set 30 rehabilitation sessions as the recommended total intervention dose and calculated rehabilitation adherence using the formula: (actual number of completed rehabilitation sessions / 30) × 100%. Based on adherence thresholds commonly applied in pharmacological and rehabilitation research, adherence is categorized as high (≥80% of the prescribed dose, ≥24 sessions), moderate (50%-79%, 15-23 sessions), or low (<50%, ≤14 sessions).

    Measured: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jul 2026
  2. Study start1 Aug 2026 (estimated)
  3. Primary completion1 Nov 2026 (estimated)
  4. Study completion1 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07714967
Sponsor's protocol ID
HYMLL-2026-280
Status last verified
Jul 2026
First submitted
30 Jun 2026
Last updated
20 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing PERMA-H model mobile-based rehabilitation support program in people with Tracheostomized Patients and Decanulation, run by Hainan Medical College at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China, Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mingxiang Li, Master (+8618389291371, 1364044138@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hope (time frame: baseline (T0), "From enrollment to the end of intervention at 4 weeks", immediately post-intervention (T1), and at one-month (T2) and three-month (T3) follow-ups). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in